Anastrozole Tablets

Buy Anastrozole Tablets Online | Anastrozole for Sale

Drug Class: Aromatase Inhibitor

Pharmaceutical Name: Anastrozole Tablets

Chemical Name: Anastrozole

Chemical Abstract Name: 2-[3-(1-cyano-1-methyl-ethyl)- 5-(1H-1,2,4-triazol-1-ylmethyl)phenyl]- 2-methyl- propanenitrile

Molecular Structure: C17H19N5

Molecular Weight: g/mol

Elimination Half Life: 48 Hours

Dosage: 0,25-1 mg/day

Presentation: Anastrozole Tablets for sale - 1 x 100 х 1mg

Manufacturer: British Dragon Pharmaceuticals

Country: Thailand

Acne: Yes

High blood pressure: May decrease if aromatizing steroids are used

Hepatotoxicity: Yes

HPTA suppression: No

Inactive ingredients: lactose, polyvidone, starch sodium glycolate, magnesium stearate, methylhydroxypropylcellulose, macrogol 300 and titanium dioxide.

Anastrozole / Pharmacological Effect

Highly selective nonsteroidal aromatase inhibitor. Aromatase - an enzyme, whereby in postmenopausal women to androstenedione in peripheral tissues is converted into estrone and then to estradiol. Reducing circulating estradiol levels has a therapeutic effect in patients with breast cancer. In postmenopausal preparation at a daily dose of 1 mg causes a decrease of estradiol levels by 80%.

Anastrozole does not have progestogenic, androgenic and estrogenic activity. Anastrozole at a daily dose of 10 mg do no effect on the secretion of cortisol and aldosterone (hence the application of the preparation does not require substitution with corticosteroids).

Anastrozole / Pharmacokinetics

Suction
After oral intake Anastrozole is rapidly absorbed from the gastrointestinal tract. Plasma C_max is reached within 2 hours (fasting). Several food reduces the rate but not the extent of absorption. Small changes in the rate of absorption should not result in a clinically significant effect on the C_SS of the drug in the plasma at a daily intake of 1 tablet of Anastrozole.

Distribution
Anastrozole binds to plasma proteins by 40%. Approximately 90-95% of the C_SS is reached after 7 days of treatment. No information about the accumulation of the drug and dependency of anastrozole pharmacokinetic parameters in time and dose.

Metabolism
Anastrozole is metabolised by N-dealkylation, hydroxylation and glucuronidation. Triazole, the major metabolite, determined in plasma and urine, does not inhibit aromatase.

Elimination
Anastrozole is eliminated slowly, T_1/2 - 40-50 hours.

Anastrozole and its metabolites are excreted primarily in the urine (at least 10% derived dose - in an unmodified form) within 72 hours after ingestion.

Pharmacokinetics in special clinical situations
Defined clearance of Anastrozole after oral intake in volunteers with stable hepatic cirrhosis or renal impairment, no different from the clearance determined in healthy volunteers.

The pharmacokinetics of Anastrozole is independent of age in postmenopausal women.

Anastrozole / Prescription

Treatment of advanced breast cancer in postmenopausal women (1 and 2 wave of hormone therapy).

In patients with a negative test result on estrogen receptors the drug's effectiveness has not been demonstrated, except in cases where there was a previous positive clinical response to tamoxifen.

Anastrozole / Dosage

Adults, including elderly patients, the drug is prescribed to 1 mg orally 1 time / day.
Patients with mild to moderate impairment of hepatic and renal function does not require dose adjustment.

Anastrozole / Side Effects

To endocrine system: hot flashes, vaginal dryness, thinning hair.

To digestive system: anorexia, nausea, vomiting, diarrhea, a small rise in total cholesterol. In patients with metastases to the liver and / or bone - raising the level of GGT, alkaline phosphatase less (causal relationship of these changes with taking Anastrozole has not been established).

CNS: drowsiness, headache.

Dermatological reactions: rash.

Other: fatigue, arthralgia, reduction of joint mobility.

Vaginal bleedings were observed infrequently, mainly in patients during the first few weeks after receiving Anastrozole prior to canceled hormonal therapy. When persistent vaginal bleeding requires additional examination.

Anastrozole / Contraindications

- preserved menstrual function;

- pregnancy;

- lactation (breastfeeding);

- hypersensitivity to anastrozole and other ingredients.

Pregnancy and Lactation

The drug is contraindicated during pregnancy and lactation (breastfeeding). In experimental studies found no teratogenic effects of the drug.

Anastrozole / Special Instructions

Do not use the drug in women of reproductive age. Status menopause must be confirmed biochemically if in doubt in the hormonal status of the patient.

No information about the safety of Anastrozole in patients with moderate and severe hepatic impairment or in patients with severe renal impairment (creatinine clearance less than 20 ml / min).

Use in Pediatrics
Anastrozole is not recommended for use in children, because its safety and efficacy in this patient group is not installed.

The results of experimental studies
In laboratory animal studies have shown low acute toxicity of Anastrozole.

Effects on ability to drive vehicles and management mechanisms
In connection with the reports of fatigue and sleepiness associated with taking Anastrozole, recommended for these symptoms to be careful while driving or moving machinery.

Anastrozole / Overdose

Cases of overdose have not been described in humans. Clinical trials conducted with various doses of Anastrozole Tablets, up to 60 mg single dose to healthy male volunteers, and 10 mg daily dose in postmenopausal women with advanced breast cancer; these doses were well tolerated. A single dose of Anastrozole at which develop life-threatening symptoms, not established.

Treatment. There is no specific antidote. If necessary spend symptomatic therapy: induction of vomiting (if patient is conscious), general supportive therapy, monitoring patients and control function of vital organs and systems.

Since Anastrozole is weakly bind to proteins, dialysis may be effective.

Anastrozole / Drug Interactions

Clinical studies on the drug interaction with antipyrine and cimetidine suggest that co-administration of Anastrozole with other drugs is unlikely to result in clinically significant interactions resulting from cytochrome P₄₅₀.

Database study of the safety of the drug accumulated in the course of clinical studies did not reveal any information about clinically significant interaction in patients treated with Anastrozole while other commonly prescribed drugs.

At the moment, there are no data on the use of Anastrozole in combination with other anticancer drugs.

Preparations containing estrogens should not be administered concurrently with Anastrozole, as they reduce the pharmacological effects of the latter.

Terms and Conditions of Storage

The drug should be stored at a temperature not exceeding 30°C. Shelf life - 3 years.

Commercial Names: Armilon, PMBC, Arimidex, Femistra, Femitraz, Qubol, Anastrozole Tablets, Altraz, Redest, Altrol, Anatero, Stazonex, Arimixyl, Armotraz, Anabrez, Aridex, Anastrocare.

Anastrozole Tablets - Anastrozole - British Dragon